Form 4: Bio-Rad CEO Reports Routine Equity Vesting and Tax Sale

Bio-Rad Laboratories' Chairman and CEO, Norman Schwartz, reported the scheduled vesting of restricted stock units and a subsequent tax-related share disposition.

Summary

• Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories, acquired 6,353 shares of Class A common stock on September 1, 2025, through the vesting of restricted stock units.
• This acquisition resulted from the vesting of three separate RSU grants: 1,266 units from a September 1, 2021 grant; 2,082 units from a September 1, 2022 grant; and 3,005 units from a September 1, 2023 grant.
• Concurrently, 3,084 shares of Bio-Rad A Common Stock were disposed of on September 1, 2025, at a price of $297.88 per share, primarily to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Mr. Schwartz directly holds 441,507 shares of Bio-Rad A Common Stock and 361,466 shares of Bio-Rad B Common Stock.
• He also indirectly holds 13,006 shares of Bio-Rad B Common Stock through his spouse and 4,060,054 shares of Bio-Rad B Common Stock through Blue Raven Partners, L.P., disclaiming beneficial ownership except for his pecuniary interest in the latter.
• Remaining derivative holdings include 2,082 and 6,010 restricted stock units directly held.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the vesting of restricted stock units and a tax-related sale. This is a neutral event, reflecting standard executive compensation practices rather than a discretionary buy or sell decision, which would typically carry more significant sentiment implications.

Positives

• The acquisition of 6,353 shares of Class A common stock through RSU vesting demonstrates continued equity ownership by the Chairman and CEO, aligning management's interests with those of shareholders.

Negatives

• The disposition of 3,084 shares of Class A common stock, while for tax purposes, results in a reduction of direct equity holdings.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership of 13,006 shares of Bio-Rad B Common Stock by spouse, with the reporting person disclaiming beneficial ownership.
• Indirect beneficial ownership of 4,060,054 shares of Bio-Rad B Common Stock by Blue Raven Partners, L.P., where the reporting person is a limited and general partner, with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The report provides transparency into executive compensation and equity holdings, which can influence investor confidence. The tax-related sale is a common occurrence and generally not seen as a negative signal.

Next Steps

• Future vesting of remaining restricted stock units on their respective schedules.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and a subsequent tax-related sale. These are non-discretionary events and do not indicate a change in management's outlook or the company's fundamentals. Therefore, the filing itself does not provide a basis for a change in investment recommendation, suggesting a 'hold' position if one was already in place, as it offers no new material information to alter a fundamental view.

Keywords

Bio-Rad Laboratories, BIO, BIO.B, Norman Schwartz, SEC Form 4, Insider Trading, Restricted Stock Units, Equity Compensation, CEO, Director, 10% Owner